Funding sources: medical writing/editorial assistance was provided by Vicki Schwartz PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

Conflicts of interest: M.A., B.S. and N.M.H.G. are employees and shareholders of Regeneron Pharmaceuticals, Inc. A.B.R. is an employee of Sanofi Genzyme and may hold stock and/or stock options in the company.

[dear editor]{.smallcaps}, Bakker *et al*. proposed that interleukin (IL)‐13 inhibition‐induced goblet‐cell decline drives dupilumab‐associated conjunctivitis in atopic dermatitis (AD).[1](#bjd18808-bib-0001){ref-type="ref"} In response, Waldman *et al*.[2](#bjd18808-bib-0002){ref-type="ref"} suggested that IL‐4 inhibition is essential, citing TREBLE, a randomized, 12‐week, placebo‐controlled, dose‐ranging phase II trial of lebrikizumab (anti‐IL‐13 monoclonal antibody) in moderate‐to‐severe AD.[3](#bjd18808-bib-0003){ref-type="ref"}

Waldman *et al*. stated that conjunctivitis incidence in TREBLE was a weaker signal than that observed with dupilumab. However, no dupilumab clinical trial publications were cited. Cross‐trial comparisons have limited value, but if such a comparison is made, the most suitable comparator is the dupilumab phase IIb trial (AD‐1021),[4](#bjd18808-bib-0004){ref-type="ref"} which was more similar to TREBLE than dupilumab phase III trials, as both AD‐1021 and TREBLE were phase II dose‐ranging trials with similar sample sizes and treatment duration. In this comparison, lebrikizumab and dupilumab conjunctivitis rates were in fact similar (see Table [1](#bjd18808-tbl-0001){ref-type="table"}).

###### 

Baseline atopic dermatitis severity and conjunctivitis incidence rates in lebrikizumab phase II (TREBLE)[3](#bjd18808-bib-0003){ref-type="ref"} and dupilumab phase IIb (AD‐1021)[4](#bjd18808-bib-0004){ref-type="ref"} randomized, placebo‐controlled clinical trials

                                                                            Baseline EASI (mean, SD)   Conjunctivitis,[a](#bjd18808-note-0005){ref-type="fn"} *n1*/*N* (%)[b](#bjd18808-note-0006){ref-type="fn"}
  ------------------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------
  *TREBLE (lebrikizumab phase 2)* [3](#bjd18808-bib-0003){ref-type="ref"}                              
  Lebrikizumab 125 mg single dose + TCS (*n* = 52)                          24·6 (11·1)                7/54 (13)
  Lebrikizumab 250 mg single dose + TCS (*n* = 53)                          26·3 (12·2)                5/52 (10)
  Lebrikizumab 125 mg q4w +TCS (*n* = 51)                                   26·9 (11·7)                3/50 (6)
  All lebrikizumab + TCS (*n* = 156)                                        n/a                        15/156 (10)
  *AD‐1021 (dupilumab phase 2b)* [4](#bjd18808-bib-0004){ref-type="ref"}                               
  Dupilumab 100 mg q4w (*n* = 65)                                           32·2 (13·5)                1/65 (2)
  Dupilumab 300 mg q4w (*n* = 65)                                           29·4 (11·5)                4/65 (6)
  Dupilumab 200 mg q2w (*n* = 61)                                           32·9 (15·5)                6/61 (10)
  Dupilumab 300 mg q2w (*n* = 64)                                           33·8 (14·5)                3/64 (5)
  Dupilumab 300 mg qw (*n* = 63)                                            30·1 (11·2)                7/63 (11)
  All dupilumab (*n* = 318)                                                 31·7 (13·4)                21/318 (7)

EASI, Eczema Area and Severity Index; HLT, MedDRA high level term; MedDRA, Medical Dictionary for Regulatory Activities; n/a, not available; *n1*/*N*, number of patients with an event, per number of patients in the safety analysis set (comprising all patients who received ≥ 1 dose of study drug, by treatment received);[3](#bjd18808-bib-0003){ref-type="ref"}, [4](#bjd18808-bib-0004){ref-type="ref"} TCS, topical corticosteroids;

q2w, every 2 weeks; q4w, every 4 weeks; qw, weekly.

MedDRA HLT of conjunctival infections, irritations and inflammation.

Patients with ≥ 1 event.
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Waldman *et al*.\'s comparison has critical limitations. Firstly, phase II trials are insufficiently sized for adequate safety assessments. Furthermore, AD severity correlates with conjunctivitis adverse events,[5](#bjd18808-bib-0005){ref-type="ref"} but baseline severity was lower in TREBLE[3](#bjd18808-bib-0003){ref-type="ref"} than AD‐1021 (see Table [1](#bjd18808-tbl-0001){ref-type="table"}) or other dupilumab trials.[4](#bjd18808-bib-0004){ref-type="ref"}, [5](#bjd18808-bib-0005){ref-type="ref"} Additionally, Medical Dictionary for Regulatory Activities (MedDRA) coding for conjunctivitis has changed over time. 'Conjunctivitis' incidence in TREBLE cannot be compared with conjunctivitis data in dupilumab labelling, which reflects multiple MedDRA preferred terms derived from comprehensive signal detection and analysis in \> 2000 study patients; IL‐13 inhibitors have not yet undergone such analyses. Finally, Waldman *et al*. cite 15·8 weeks for dupilumab‐associated conjunctivitis from a 12‐patient case series;[6](#bjd18808-bib-0006){ref-type="ref"} however, in TREBLE, treatment was for ≤ 12 weeks,[3](#bjd18808-bib-0003){ref-type="ref"} likely underestimating IL‐13 blockade effects.

Conjunctivitis seen in dupilumab AD trials is a complex, multifactorial phenomenon.[5](#bjd18808-bib-0005){ref-type="ref"} In addition to IL‐13‐driven goblet‐cell effects, epithelial barrier disruption in AD (demonstrably improved by dupilumab) also likely plays a role. Indeed, higher dupilumab serum concentrations were associated with less conjunctivitis in AD trials,[5](#bjd18808-bib-0005){ref-type="ref"} and conjunctivitis was not an issue in asthma trials of dupilumab (very low rates, similar for dupilumab and placebo).[5](#bjd18808-bib-0005){ref-type="ref"} Conjunctivitis usually resolves while patients are on dupilumab and is rarely treatment limiting,[5](#bjd18808-bib-0005){ref-type="ref"} supporting the epithelial barrier role.

Waldman *et al*.\'s evidence does not support IL‐4 inhibition as a driver of conjunctivitis. Current phase II data on IL‐13 blockade are too limited to discriminate potential ocular effects of IL‐13 and IL‐4.
